Advertisement

Topics

Companies Related to "Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer" [Most Relevant Company Matches] RSS

08:33 EST 21st February 2019 | BioPortfolio

Here are the most relevant search results for "Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer" found in our extensive corporate database of over 50,000 company records.

Showing "Monoclonal Antibody A1G4 Plus Treating Patients With Cancer" Companies 1–25 of 6,100+

Extremely Relevant

A&G Pharmaceutical Incorporated

A&G Pharmaceutical, Inc. (A&G) was incorporated in Delaware on June 6, 2000, as a "C" Corporation, to make use of two proprietary technologies that are unique to the Company. A&G is located in Baltimore, Maryland, and consists of two distinct but integrate divisions: 1) the Pharmaceutical Division and 2) the Monoclonal Antibody Services Division. Pharmaceutical Division Breast cancer is the most ...


KaloBios Pharmaceuticals, Inc.

KaloBios Pharmaceuticals, Inc., a U.S. based, private monoclonal company, uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. The company has multiple programs that have been in seven Phase 1 or 2 clinical trials in the last few years. KB001 is a PEGylated monoclonal antibody fragmen...

OncoResponse

OncoResponse discovers and develops highly targeted and immuno-oncology therapeutic antibodies against novel cancer targets. Our most advanced program, ONCR-201 is an anti-EMP2 fully-human monoclonal antibody being developed for female malignancies. The OncoResponse discovery engine is working to increase the success rate of cancer immunotherapies by ident...


Abnova Corporation

Abnova is the world largest monoclonal antibody manufacturer. We have a capacity of generating 500 mouse monoclonal antibodies per month. Rather than the traditional method of monoclonal antibody production, Abnova is taking a genomic/proteomic approach for the antibody development. Our goal is to have at least one antibody to every human expressed gene in human genome. We manufacture all our prod...

Abnova Corporation

Abnova is the world largest monoclonal antibody manufacturer. We have a capacity of generating 500 mouse monoclonal antibodies per month. Rather than the traditional method of monoclonal antibody production, Abnova is taking a genomic/proteomic approach for the antibody development. Our goal is to have at least one antibody to every human expressed gene in human genome. We manufacture all our prod...

Relevant

ModiQuest Research

Monoclonal Antibody Therapeutics and Diagnostics For Rheumatoid Arthritis & Cancer ModiQuest Group was founded in 2004 and is based in Nijmegen, The Netherlands. It consists of ModiQuest Therapeutics B.V, focused on the development of novel monoclonal antibody therapeutics and diagnostics for autoimmune and oncology targets, and ModiQuest Research, which provides technology and contract re...

Lpath

Lpath, Inc., headquartered in San Diego, California, is a theranostics company focused on bioactive signaling lipids as targets for treating and diagnosing important human diseases. Lpath's lead product candidate, Sphingomab™, is a monoclonal antibody (mAb) against a validated cancer target, sphingosine-1-phosphate (S1P), and has demonstrated compelling results against six different forms of sol...

InNexus Biotechnology, Inc.

approaches that add secondary properties to monoclonal antibodies (binding is a primary property) and applies to virtually every antibody product currently in development. Adding these secondary properties can increase the potency of antibodies or add new properties such as the ability to penetrate into living cells.As an example, InNexus utilized SAT with a humanized monoclonal antibody, licensed...

Trellis Bioscience

Monoclonal antibody technology was the research breakthrough of the 1980’s. With the discovery by Milstein and Kohler in Cambridge, England, Hybritech became the first company dedicated to the production of monoclonal antibodies, commercializing the first diagnostic tests and leading to two subsequent companies that furthered monoclonal antibody development, GenProbe and IDEC. The use of monoclo...

Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (“OMT”) is a private biotechnology company with a new, fully human monoclonal antibody platform based on transgenic rats. The rat is a widely used laboratory animal with a well characterized immune system, a nearly complete genome sequence, and established transgenesis and hybridoma technologies. OMT’s antibody ...

HealthCare Pharmaceuticals, Inc.

HealthCare Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel, targeted therapies for the treatment of patients with cancer. DKN-01, our clinical-stage monoclonal antibody, is currently being tested in Phase 1b and Phase 2 clinical trials for patients with DKK1+ esophageal cancer and multiple mye...

TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals is a privately held biotechnology company focused on the development of products for oncology and ophthalmology treatment, including agents that inhibit angiogenesis. TRACON addresses unmet needs in these areas with first-in-class product candidates that will complement existing therapies. TRC093 is a monoclonal antibody that binds to cleaved collagen to inhibit angiogenesis...

ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a ...

ImmunoCellular Therapeutics

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a ...

Antibodies by Design

Antibodies by Design uses proven MorphoSys recombinant antibody technology to provide high quality monoclonal antibodies to its customers in record time. The HuCAL GOLD® library contains over 15 billion unique human antibody genes in Fab format. This wealth and diversity of sequences is coupled with proprietary automated screening techniques and advanced data management systems to quickly identif...

Cambridge Antibody Technology

Cambridge Antibody Technology (CAT) is a biopharmaceutical company committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives.CAT has strong financial foundations, good medium term prospects and significant opportunities for growth in the longer term.

A&G Pharmaceutical, Inc.

A&G was incorporated in Delaware as a “C” Corporation on June 6, 2000. The company is located in Columbia, Maryland and has 12 employees occupying 6,725 square feet of lab space. A&G has raised $3.5 million in capital to date and is looking to finish clinical trials and FDA submission for 2 diagnostic kits for breast cancer. Besides our own theranostic product development, A&G has a unique pro...

Viventia Biotech Inc

Viventia Biotech Inc. is a biopharmaceutical company advancing a new generation of monoclonal antibody therapeutics designed to offer safer, more beneficial therapies for cancer patients. Viventia’s lead product candidate Proxinium™ continues on an aggressive clinical development schedule. Viventia has initiated a Phase II North American clinical trial and concurrently commenced a pivotal Phas...

Acceptys, Inc.

Acceptys is a private biotechnology company focused on the development of human antibody therapies in cancer and infectious diseases. The Company's key strength is its ability to directly leverage the power of the human immune system, which has continually evolved with the specific purpose of preserving health. More specifically, Acceptys can capture thousands of antibodies from strategically targ...

Epitomics, Inc.

Epitomics, Inc., an emerging biotechnology company, is dedicated to developing breakthrough monoclonal antibody technology for research, diagnostic and therapeutic applications. The company utilizes a unique and proprietary RabMAb® (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays. Epitomics, Inc...

MacroGenics, Inc.

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. Since its founding in 2000, the company has built a fully-integrated set of capabilities in monoclonal antibody product development. The company's product development efforts leverage three ...

Mathison Immuno Scientific Incorporated

CUSTOM MONOCLONAL ANTIBODY SERVICE Difficult epitopes are our specialty. Antibody available in culture supernatant or ascites. Antibody purified to your specific requirements Competitive prices & Stepwise payment plan Confidentiality guarantee

Cytogen

Cytogen is a specialty pharmaceutical company dedicated to advancing the treatment and care of cancer patients by building, developing, and commercializing a portfolio of oncology products. The Company's specialized sales force currently markets QUADRAMET® (samarium Sm-153 lexidronam injection), PROSTASCINT® (capromab pendetide), and SOLTAMOX™ (tamoxifen citrate) to the U.S. oncology market. Q...

Nascent Biotech Inc.

NBI is a biotechnology company developing human Monoclonal Antibodies (mAb’s) for immunotherapy of cancer. Its lead therapeutic candidate, Pritumumab, was the first human antibody ever developed to treat a cancer patient and has been validated in 249 patients in Japan. The company is now developing a new clinical protocol and Initial New Drug (IND) pa...

f-star

F-star is a biopharmaceutical company dedicated to developing novel bispecific antibody products that provide a significant improvement over the current standard of care. Given its strong patent position, it is the only biopharmaceutical company with the ability to create and develop Fcab™ antibody fragments, and bispecific antibodies, by modifying th...


More From BioPortfolio on "Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks